Want to see IN:AKUMS full AI Analyst Report?
AKUMS Stock Chart & Stats
₹684.40
-₹11.70(-1.70%)
At close: 4:00 PM EDT
₹684.40
-₹11.70(-1.70%)
Day’s Range― - ―
52-Week Range₹410.10 - ₹713.80
Previous CloseN/A
Volume178.53K
Average Volume (3M)11.50K
Market Cap
₹103.74B
Enterprise Value₹56.30K
Total Cash (Recent Filing)₹16.78B
Total Debt (Recent Filing)₹902.87M
Price to Earnings (P/E)39.5
Beta1.20
Next Earnings
Aug 08, 2026EPS Estimate
6.1Next Dividend Ex-DateN/A
Dividend Yield0.45%
Share Statistics
EPS (TTM)12.42
Shares Outstanding157,393,980
10 Day Avg. Volume12,021
30 Day Avg. Volume11,497
Financial Highlights & Ratios
PEG Ratio-1.07
Price to Book (P/B)2.15
Price to Sales (P/S)1.64
P/FCF Ratio7.28
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)23.45
Revenue Forecast (FY)₹49.24B
Bulls Say, Bears Say
Bulls Say
Strong Balance SheetDebt-to-equity dropped dramatically to near-zero levels in FY25–FY26, materially reducing financial risk and increasing strategic optionality. A stronger capital base supports sustained operations, capacity investments or selective M&A without straining cash flow over the medium term.
Improved Cash GenerationOperating and free cash flows turned strongly positive in FY26 and covered a large portion of earnings, which enhances self-funding ability for capex, working capital and shareholder returns. Consistent cash generation strengthens resilience vs cyclical demand shifts in pharma.
CDMO/CRAMS Business ModelA contract manufacturing and development model captures structural outsourcing trends in pharma, providing diversified revenue streams across therapies and geographies. Long-term client relationships and repeat orders support steady base volumes and scale-driven cost absorption.
Bears Say
Margin CompressionA sharp FY26 margin decline signals pricing, cost or mix pressures that can materially reduce profitability even if revenue grows. Persistent margin erosion would impair return on capital, free cash flow potential and ability to fund growth without lifting prices or improving operational efficiency.
Volatile Earnings & Cash ConversionHistoric swings from negative to positive cash flow and a FY26 FCF decline versus FY25 indicate unstable earnings-to-cash conversion. Such volatility makes forecasting investment capacity and dividends harder, and raises execution risk for sustaining capex or service levels.
Limited Brand Control / Pricing PowerRelying on third-party branded customers reduces direct pricing influence and increases exposure to customer bargaining and contract renewal risks. Over time this can compress margins and leave growth tied to client demand rather than end-market branding or channel control.
Akums Drugs and Pharmaceuticals Limited News
AKUMS FAQ
What was Akums Drugs and Pharmaceuticals Limited’s price range in the past 12 months?
Akums Drugs and Pharmaceuticals Limited lowest stock price was ₹410.10 and its highest was ₹713.80 in the past 12 months.
What is Akums Drugs and Pharmaceuticals Limited’s market cap?
Akums Drugs and Pharmaceuticals Limited’s market cap is ₹103.74B.
When is Akums Drugs and Pharmaceuticals Limited’s upcoming earnings report date?
Akums Drugs and Pharmaceuticals Limited’s upcoming earnings report date is Aug 08, 2026 which is in 2 days.
How were Akums Drugs and Pharmaceuticals Limited’s earnings last quarter?
Akums Drugs and Pharmaceuticals Limited released its earnings results on May 14, 2026. The company reported ₹5.5 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Akums Drugs and Pharmaceuticals Limited overvalued?
According to Wall Street analysts Akums Drugs and Pharmaceuticals Limited’s price is currently Overvalued.
Does Akums Drugs and Pharmaceuticals Limited pay dividends?
Akums Drugs and Pharmaceuticals Limited pays a Notavailable dividend of ₹3 which represents an annual dividend yield of 0.45%. See more information on Akums Drugs and Pharmaceuticals Limited dividends here
What is Akums Drugs and Pharmaceuticals Limited’s EPS estimate?
Akums Drugs and Pharmaceuticals Limited’s EPS estimate is 6.1.
How many shares outstanding does Akums Drugs and Pharmaceuticals Limited have?
Akums Drugs and Pharmaceuticals Limited has 157,393,980 shares outstanding.
What happened to Akums Drugs and Pharmaceuticals Limited’s price movement after its last earnings report?
Akums Drugs and Pharmaceuticals Limited reported an EPS of ₹5.5 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.69%.
Which hedge fund is a major shareholder of Akums Drugs and Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in IN:AKUMS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Akums Drugs and Pharmaceuticals Limited
Akums Drugs & Pharmaceuticals Ltd. is an Indian-based company, established in 2004 and headquartered in Delhi, that operates globally as a manufacturer and supplier of both finished pharmaceutical products and active pharmaceutical ingredients (APIs). Its diverse product range encompasses conventional drugs, traditional Ayurvedic and herbal remedies, personal care items including toiletries, nutraceuticals, food and dietary supplements, dermatological and cosmetic products, and healthcare and hospital supplies, along with over-the-counter (OTC) solutions. The company also deals in excipients and various chemical compounds. Akums develops and markets its own branded formulations across a variety of dosage forms, such as tablets, capsules, injectables, ophthalmic preparations, and soft gelatin capsules. These products address a broad spectrum of therapeutic areas, including gynaecology, cardiology, orthopaedics, pediatrics, dermatology, anti-infectives, pain management, and gastroenterology. Furthermore, Akums Drugs & Pharmaceuticals provides services as a pharmaceutical contract development and manufacturing organization (CDMO).
Technical Analysis
Glenmark Life Sciences Limited
―
Jubilant Pharmova Limited
―
Shilpa Medicare Limited
―
Strides Pharma Science Ltd
―
Sudeep Pharma Limited
―